Abstracts tagged "Juvenile dermatomyositis and treatment"

Abstract Number: 1368 • 2016 ACR/ARHP Annual Meeting
Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease
Edward J. Oberle^1,2, Dominic O. Co^3,4, Yvonne Chiu^3,4, Michelle Bayer^4,5, Adam Huber⁶, Hatice Ezgi Baris⁷ and Susan Kim⁸, ¹Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Pediatrics, Ohio State University, Columbus, OH, ³Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁴Children's Hospital of Wisconsin, Milwaukee, WI, ⁵Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁶Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁷Boston Children's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of the skin and striated muscle. A subset of patients can present with rash only, labeled…
Abstract Number: 297 • 2012 ACR/ARHP Annual Meeting
Effectiveness of Intravenous Cyclophosphamide in Severe or Refractory Juvenile Dermatomyositis – A National Cohort Study: UK and Ireland
Elena Moraitis¹, Katie Arnold², Clarissa Pilkington³ and Juvenile Dermatomyositis Research Group⁴, ¹Rheumatology, Great Ormond Street Hospital, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁴London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune vasculopathy affecting primarily the muscle and skin, but can also involve other organs. Early and aggressive treatment improves outcome and prevents complications. Cyclophosphamide has been used as a second-line agent in the treatment of severe or refractory JDM. The published literature on the effectiveness of cyclophosphamide in JDM is limited to a small case series and case reports.The objective of the study is to describe the response to cyclophosphamide in the patients with severe or refractory JDM. Methods: 56 patients treated with cyclophosphamide between years 2000-2011 were identified in the JDM National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. 8 patients were excluded due to incomplete data or too short follow up. For the 48 patients included, demographics, myositis core outcome variables, skin measures, laboratory measures, steroid dose and other treatments were recorded at baseline, time 6, 12, 18, 24 months and last follow up post commencement of the drug.Results: Indications for starting cyclophosphamide were ulcerative or severe skin disease, profound muscle weakness, lung disease, gastro-intestinal vasculopathy or refractory disease. Previous medications were steroids and Methotrexate for 47 patients and steroids and Cyclosporin for 1 patient. All patients starting with muscle weakness (n=44) significantly improved at time12, and the gains were maintained at follow up (see table1). Physician VAS was available for 32 patients and these all improved by 12 and 24 months, and for 31 remained stable at follow up. At last follow up 26/46(56%) had no rash, 32/46(69%) had normal nailfolds, 37/45(82%) had no Gottron’s, and calcinosis improved in 9/14(64%). Conclusion: This study, the largest to date, demonstrated significant improvement in both muscle and skin domains in patients with JDM treated with intravenous cyclophosphamide.Cyclophosphamide appears effective in the treatment of severe or refractory JDM.Table 1Table 2

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].